Q2 2025 Elutia Inc Earnings Call Transcript
Key Points
- Elutia Inc (ELUT) reported a 49% sequential growth in EluPro sales, driven by securing seven national GPO contracts and expanding into 161 hospital systems.
- The company has developed a strong partnership with Boston Scientific, which is actively involved in EluPro sales in 98 hospitals, facilitating 30% of EluPro cases.
- Elutia Inc (ELUT) has achieved significant recognition for its drug-eluting technology, winning multiple awards including the Edison Award and Medical Device Network Excellence Awards.
- The company is making substantial progress in the breast reconstruction market with its NXT-41x platform, aiming to address significant unmet medical needs.
- Elutia Inc (ELUT) has settled 97 out of 110 lawsuits related to a past product recall, reducing legal expenses and removing a significant overhang on the company.
- Elutia Inc (ELUT) faces challenges in scaling VAC approvals, which are crucial for revenue growth, with a current target of 1,600 hospital centers.
- The company is still dealing with 13 unresolved lawsuits from a past product recall, which continue to pose a potential financial and reputational risk.
- SimpliDerm sales have underperformed, generating $2 million in revenue, which is lower than previous quarters.
- Elutia Inc (ELUT) reported a $3.8 million adjusted EBITDA loss for the quarter, indicating ongoing financial challenges despite revenue growth.
- The company has $8.5 million in cash, which may be insufficient for future growth initiatives without successful business development transactions.
Good afternoon, ladies and gentlemen. Welcome to Elutia's second-quarter 2025 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Matt Steinberg with FINN Partners. Thank you. You may begin.
Thank you, operator, and thank you, all, for participating in today's call. Earlier today, Elutia released financial results for the quarter ended June 30, 2025. A copy of the press release is available on the company's website.
Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results, or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
